Tags

Type your tag names separated by a space and hit enter

Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine.

Abstract

Yearly influenza vaccination is recommended for patients with humoral primary immunodeficiency (hPID). However, humoral responses following vaccination can be expected to be reduced in these patients. The efficacy of influenza vaccination in patients with hPID, anti-influenza antibody responses was assessed in 26 patients with hPID and 26 matched healthy controls (HC) using hemagglutination inhibition assay. Following vaccination, geometric mean titers (GMT) significantly increased for all influenza strains in the HC group, but only for A/H1N1 in the patient group. Fold increase in anti-influenza titer and seroprotection rates were lower for patients than for HC for A/H3N2 and A/H1N1, leading to postvaccination titer > or =40 in only 29% and 83% vs. 77% and 100%, respectively. Previous vaccination in patients and treatment with IVIg did not result in a higher rate of postvaccination titer > or =40. In conclusion, patients with hPID show hardly any humoral response following influenza vaccination.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands. s.van.assen@int.umcg.nl

    , , , , , ,

    Source

    Clinical immunology (Orlando, Fla.) 136:2 2010 Aug pg 228-35

    MeSH

    Adult
    Antibodies, Viral
    Case-Control Studies
    Female
    Humans
    Immunoglobulins, Intravenous
    Immunologic Deficiency Syndromes
    Influenza A Virus, H1N1 Subtype
    Influenza A Virus, H3N2 Subtype
    Influenza Vaccines
    Influenza, Human
    Male
    Middle Aged
    Vaccines, Subunit

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    20421178

    Citation

    van Assen, Sander, et al. "Patients With Humoral Primary Immunodeficiency Do Not Develop Protective Anti-influenza Antibody Titers After Vaccination With Trivalent Subunit Influenza Vaccine." Clinical Immunology (Orlando, Fla.), vol. 136, no. 2, 2010, pp. 228-35.
    van Assen S, Holvast A, Telgt DS, et al. Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. Clin Immunol. 2010;136(2):228-35.
    van Assen, S., Holvast, A., Telgt, D. S., Benne, C. A., de Haan, A., Westra, J., ... Bijl, M. (2010). Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. Clinical Immunology (Orlando, Fla.), 136(2), pp. 228-35. doi:10.1016/j.clim.2010.03.430.
    van Assen S, et al. Patients With Humoral Primary Immunodeficiency Do Not Develop Protective Anti-influenza Antibody Titers After Vaccination With Trivalent Subunit Influenza Vaccine. Clin Immunol. 2010;136(2):228-35. PubMed PMID: 20421178.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. AU - van Assen,Sander, AU - Holvast,Albert, AU - Telgt,Denise S C, AU - Benne,Cornelis A, AU - de Haan,Aalzen, AU - Westra,Johanna, AU - Kallenberg,Cees G M, AU - Bijl,Marc, Y1 - 2010/04/24/ PY - 2009/08/21/received PY - 2010/03/19/revised PY - 2010/03/29/accepted PY - 2010/4/28/entrez PY - 2010/4/28/pubmed PY - 2010/8/6/medline SP - 228 EP - 35 JF - Clinical immunology (Orlando, Fla.) JO - Clin. Immunol. VL - 136 IS - 2 N2 - Yearly influenza vaccination is recommended for patients with humoral primary immunodeficiency (hPID). However, humoral responses following vaccination can be expected to be reduced in these patients. The efficacy of influenza vaccination in patients with hPID, anti-influenza antibody responses was assessed in 26 patients with hPID and 26 matched healthy controls (HC) using hemagglutination inhibition assay. Following vaccination, geometric mean titers (GMT) significantly increased for all influenza strains in the HC group, but only for A/H1N1 in the patient group. Fold increase in anti-influenza titer and seroprotection rates were lower for patients than for HC for A/H3N2 and A/H1N1, leading to postvaccination titer > or =40 in only 29% and 83% vs. 77% and 100%, respectively. Previous vaccination in patients and treatment with IVIg did not result in a higher rate of postvaccination titer > or =40. In conclusion, patients with hPID show hardly any humoral response following influenza vaccination. SN - 1521-7035 UR - https://www.unboundmedicine.com/medline/citation/20421178/Patients_with_humoral_primary_immunodeficiency_do_not_develop_protective_anti_influenza_antibody_titers_after_vaccination_with_trivalent_subunit_influenza_vaccine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1521-6616(10)00530-9 DB - PRIME DP - Unbound Medicine ER -